Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Evaluation of a technology assisted physical activity intervention among hospitalised patients: A randomised study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of compression stocking on leg edema and discomfort during a 3-hour flight: A randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. An international perspective on hospitalized patients with viral community-acquired pneumonia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone, secreted in response to ingestion of nutrients, and has important effects on several of the pathophysiological features of type 2 diabetes (T2D). The effects include potentiation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and suppression of appetite. In circulation, GLP-1 has a half-life of approximately 2min due to rapid degradation by the enzyme dipeptidyl peptidase 4 (DPP-4). Because of this short half-life GLP-1 receptor (GLP-1R) agonists, resistant to degradation by DPP-4 have been developed. At the moment four different compounds are available for the treatment of T2D and many more are in clinical development. These compounds, although all based on the effects of native GLP-1, differ with regards to structure, pharmacokinetics and size, which ultimately leads to different clinical effects. This review gives an overview of the clinical data on GLP-1R agonists that have been compared in head-to-head studies and focuses on relevant differences between the compounds. Highlighting these similarities and differences could be beneficial for physicians in choosing the best treatment strategy for their patients.

Original languageEnglish
JournalEuropean Journal of Internal Medicine
Volume25
Issue number5
Pages (from-to)407-14
Number of pages8
ISSN0953-6205
DOIs
Publication statusPublished - Jun 2014

ID: 44428310